🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to scientists.

A Global Public Health Issue

The sexually transmitted infection are escalating worldwide, with data suggesting more than 82 million instances annually. Notably increased rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, the spread of superbugs and the extremely scarce available drugs currently available.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The WHO has listed it as a "high-priority threat". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Clearance

Zoliflodacin, alternatively called a brand name, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is employed against UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to see it through.

“This authorization signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Research Study Data and Global Access

According to results released by a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This places it at an comparable level with the typical regimen, which combines a dual-drug approach. The research involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to make available and distribute the drug in many low-income and middle-income countries.

Doctors on the front lines have voiced hope. The availability of a easy-to-administer therapy of this kind is described as a "critical tool" for public health efforts. This is considered essential to reduce the burden of the infection for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.